Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Safety, immunogenicity and protective effect of sequential vaccination with inactivated and recombinant protein COVID-19 vaccine in the elderly: a prospective longitudinal study

Fig. 2

Safety evaluation. The incidence of adverse events within 1 month after each dose of COVID-19 vaccine (a) and the proportion of each adverse event to the overall in two groups within 1 month after the first dose (b), the second dose (c), and the booster (d). Changes in the biochemical indices in two groups at baseline and the 1st, 2nd, 4th, 7th, 8th, 10th, and 13th months (data of the 16th month was not detected due to the pandemic interference) shown in e–n. *P < 0.05; ns no significance; GGT γ-glutamyl transpeptidase; ALP alkaline phosphatase. Other adverse events included rash, cough, pharyngeal malaise, tinnitus, and insomnia

Back to article page